TY - JOUR T1 - Serum Amyloid A: a Biomarker for Renal Cancer JF - Anticancer Research JO - Anticancer Res SP - 1801 LP - 1804 VL - 32 IS - 5 AU - KERSTEN FISCHER AU - GERIT THEIL AU - RASCHID HODA AU - PAOLO FORNARA Y1 - 2012/05/01 UR - http://ar.iiarjournals.org/content/32/5/1801.abstract N2 - Background/Aim: Serum amyloid A (SAA) has been identified as a potential biomarker for renal cell carcinoma. We examined its diagnostic value in patients of different tumor stages. Patients and Methods: In our study, 48 patients with localized and 67 patients with advanced renal tumors were included. 24 patients served as a control group. Interleukine 6 (IL-6), C-reactive protein (CRP) and SAA levels were measured preoperatively and at day 5 after nephrectomy. Results: The IL-6, CRP and SAA levels in patients with advanced tumors are significantly higher than those of patients with localized tumors. Advanced tumors were identified with a sensitivity of 78% (SAA), 69% (CRP) and 44% (IL-6). The specificity was 82%, 82% and 94% for SAA, CRP and IL-6, respectively. Conclusion: Our results indicate that advanced renal cancers are accompanied by increased levels of acute-phase proteins such as CRP and SAA. SAA is found to be more sensitive than CRP for the indication of advanced renal cancer. ER -